Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity

A team of US-based scientists recently demonstrated that pro-thrombotic autoantibodies that target angiotensin II type 1 receptor (AT1R) may be associated with endothelial complications observed in coronavirus disease 2019 (COVID-19), a novel disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is currently available on the medRxiv* preprint server.

Study: Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection. Image Credit: youneed.graphics / Shutterstock
Study: Angiotensin II receptor I auto-antibodies following SARS-CoV-2 infection. Image Credit: youneed.graphics / Shutterstock

Background

Hypercoagulation and thrombosis are the major hallmarks of severe COVID-19. Studies investigating the mechanism of endothelial dysfunction in COVID-19 patients have suggested that coagulopathy may result from direct endovascular damage, abnormal platelet functioning, or infection-induced pro-thrombotic autoantibodies.

According to available literature, anti-endothelial antibodies that are directed against AT1R can potentially increase the risk of hypertension, preeclampsia, and renal transplant-related vascular rejection. Particularly, AT1R-targeting autoantibodies directed against the second extracellular loop of the receptor are associated with increased proinflammatory cytokine production, increased disease severity in preeclampsia (pregnancy-related high blood pressure), and aberrant coagulation and blood clot formation. In severe COVID-19, multi-organ endothelial inflammation may increase the development of anti-endothelial AT1R-targeting antibodies. Moreover, structural similarities between SARS-CoV-2 spike epitopes and the second extracellular loop of AT1R may result in the development of cross-reactive antibodies.  

Given these observations, the scientists in the current study have investigated the role of AT1R-targeting autoantibodies in mediating hypercoagulation in COVID-19. Moreover, they have assessed whether SARS-CoV-2-negative individuals with AT1R-targeting autoantibodies exhibit cross-reactivity against the viral spike trimer.

Study design

Screening of AT1R-targeting autoantibodies was conducted using plasma samples derived from patients with mild or severe COVID-19. As experimental controls, plasma samples from seronegative individuals without a history of COVID-19-like illness were also assessed. Moreover, structural modeling experiments were performed to identify structurally similar regions between AT1R and SARS-CoV-2 spike protein.

Important observations

A comparable proportion of individuals with AT1R-targeting autoantibodies was identified among mild COVID-19 patients and healthy controls. However, a higher proportion of AT1R autoantibody-positive individuals was identified among severe COVID-19 patients as compared to that among healthy controls.

Although not statistically significant, higher levels of AT1R-targeting autoantibodies were observed in mild COVID-19 patients compared to that in healthy controls. In contrast, no such difference in antibody levels was observed between severe COVID-19 patients and healthy controls.

Among patients with severe COVID-19, comparatively higher levels of AT1R-targeting autoantibodies were observed in those with thrombotic events, including myocardial infarction, pulmonary embolism, and deep-vein thrombosis.

Based on the prediction made by structural homology assessments, there could be potential antibody cross-reactivity between the S2 subunit of the SARS-CoV-2 spike and AT1R.

To test the prediction, further experiments were conducted with samples obtained from healthy controls with or without AT1R-targeting autoantibodies. The findings revealed that AT1R autoantibody positivity status is not associated with reactivity to SARS-CoV-2 spike trimer. Moreover, a low level of cross-reactivity was observed between AT1R-targeting autoantibodies and the SARS-CoV-2 receptor binding domain and nucleocapsid protein.     

Study significance

The study highlights a possible association between AT1R-targeting autoantibodies and COVID-19 severity. Specifically, the study suggests that AT1R autoantibody positivity status may increase the risk of endothelial complications in COVID-19 patients.

However, since the scientists could not determine whether these antibodies are pre-existing or developed in response to SARS-CoV-2 infection, they are unable to understand whether naive individuals with AT1R autoantibodies are more susceptible to develop severe COVID-19 if infected with SARS-CoV-2.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Dr. Sanchari Sinha Dutta

Written by

Dr. Sanchari Sinha Dutta

Dr. Sanchari Sinha Dutta is a science communicator who believes in spreading the power of science in every corner of the world. She has a Bachelor of Science (B.Sc.) degree and a Master's of Science (M.Sc.) in biology and human physiology. Following her Master's degree, Sanchari went on to study a Ph.D. in human physiology. She has authored more than 10 original research articles, all of which have been published in world renowned international journals.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dutta, Sanchari Sinha. (2021, July 06). Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity. News-Medical. Retrieved on July 24, 2021 from https://www.news-medical.net/news/20210706/Angiotensin-II-type-1-receptor-targeting-autoantibodies-may-increase-COVID-19-severity.aspx.

  • MLA

    Dutta, Sanchari Sinha. "Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity". News-Medical. 24 July 2021. <https://www.news-medical.net/news/20210706/Angiotensin-II-type-1-receptor-targeting-autoantibodies-may-increase-COVID-19-severity.aspx>.

  • Chicago

    Dutta, Sanchari Sinha. "Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity". News-Medical. https://www.news-medical.net/news/20210706/Angiotensin-II-type-1-receptor-targeting-autoantibodies-may-increase-COVID-19-severity.aspx. (accessed July 24, 2021).

  • Harvard

    Dutta, Sanchari Sinha. 2021. Angiotensin II type 1 receptor-targeting autoantibodies may increase COVID-19 severity. News-Medical, viewed 24 July 2021, https://www.news-medical.net/news/20210706/Angiotensin-II-type-1-receptor-targeting-autoantibodies-may-increase-COVID-19-severity.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
SARS-CoV-2 immunity due to prior infection or vaccination is similar, study says